Enoxaparin for Regional Anesthesia Morbidity

"There is ample clinical evidence confirming Enoxaparin's safety, resulting in a rating of 3."

"Affirmative, the information hosted on clinicaltrials.gov reveals that this investigation is presently recruiting volunteers. The trial was initially published on October 24th 2017 and most recently updated December 16th 2021. 150 participants need to be enlisted over 1 medical centre."

"This clinical trial welcomes those aged 18 and over, but no older than 100 years of age."

"Clinicaltrials.gov confirms that this medical research project is actively accepting participants; the trial was first promoted on October 24th 2017 and underwent its most recent update December 16th 2021."

"This trial aims to assess the anti-Xa activity levels over a 24 or 36 hour period after the patient's last dose of enoxaparin. Additionally, this study plans to examine how patients' weights and ages may contribute to an increase in anti-Xa level results that exceeds one standard deviation from their mean values. Finally, investigators will attempt to discern the relationship between these measures and anti-Xa level outcomes across time."

"This clinical trial is seeking 150 individuals suffering from hemostatic disorders aged between 18 and 100. To be eligible, they must have been prescribed a treatment dose (1mg/kg twice daily or 1.5mg/kg daily) of enoxaparin at the time of presentation for elective surgery, able to accurately report the timing of their last dose and dosage taken, as well provide written consent to participate in this study."

"Enoxaparin is medically recommended for treating acute chest syndrome, outpatient care and managing unstable angina."

"Currently, 20 different clinical studies are actively evaluating the efficacy of Enoxaparin with 6 trials in Phase 3. Although Saint Louis Missouri is conducting several experiments on this drug, another 363 sites throughout the world have chosen to also participate."